Keywords
Polychemotherapy
Side Effects
Anticancer Agents
How to Cite
Abstract
Cancer is a leading cause of millions of deaths worldwide and, despite the improvements in molecular biology, issues concerning how to advance cancer treatment are still relevant. Cancer research must be focused on finding new and efficient chemotherapeutic regimens that can relieve severe side effects caused by conventional treatments. Modern technologies are currently under estimation in clinical trials or have already been introduced into clinical practice. Nowadays cancer therapy is characterized by ineffectiveness and serious side effects, as well as by hope of remission and cure in many cases. Antitumor drugs and radiation have been used as the treatment of choice in some cancer cases, except for the choice of surgery in case of solid tumors. Recently, immunotherapy has emerged as a significant therapeutic alternative, and in many cases, it is the first choice. These therapies can be applied either alone or in combination with other agents. Additionally, gene treatment and nanotechnology are promising methods for cancer treatment as well. The current review presents the progress of cancer treatments, starting with surgery, chemotherapy, radiation and immunotherapy, gene treatment and nanomedicine, giving emphasis to the most common anticancer agents and polychemotherapeutic regimens.
References
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology. 2017;15(2):81–94. Available from: https://doi.org/10.1038/nrclinonc.2017.166
Savage P. Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. BMC Cancer. 2015;15(1):11. Available from: https://doi.org/10.1186/s12885-015-1006-6
Moxley JH, De Vita VT, Brace K, Frei E. III. Intensive combination chemotherapy and X-irradiation in Hodgkin’s disease. Cancer Res. 1967;27:1258-1263.
Devita VT. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Annals of Internal Medicine. 1970;73(6):881-895. Available from: https://doi.org/10.7326/0003-4819-73-6-881
Devita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. The Lancet. 1975;305(7901):248–50. Available from: https://doi.org/10.1016/S0140-6736(75)91142-3
Einhorn LH. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Annals of Internal Medicine. 1977;87(3):293-298. Available from: https://doi.org/10.7326/0003-4819-87-3-293
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Seminars in Oncology. 2009;36(3):237–249. Available from: https://doi.org/10.1053/j.seminoncol.2009.03.001
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer. 2018;17(1):48. Available from: https://doi.org/10.1186/s12943-018-0804-2
Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. Journal of Cancer Research and Clinical Oncology. 2014;141(5):769–784. Available from: https://doi.org/10.1007/s00432-014-1767-3
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine. 2005;353(2):172–187. Available from: https://doi.org/10.1056/NEJMra044389
Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. The Oncologist. 2009;14(8):800–805. Available from: https://doi.org/10.1634/theoncologist.2009-0088
Hofheinz R-D, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs. 2005;16(7):691–707. Available from: https://doi.org/10.1097/01.cad.0000167902.53039.5a
Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioengineering. 2019;3(1):011502. Available from: https://doi.org/10.1063/1.5079943
Kumar B, Garcia M, Murakami JL, Chen C-C. Exosome-mediated microenvironment dysregulation in leukemia. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2016;1863(3):464–470. Available from: https://doi.org/10.1016/j.bbamcr.2015.09.017
Lebedeva IV, Su Z-Z, Sarkar D, Fisher PB. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Seminars in Cancer Biology. 2003;13(2):169–178. Available from: https://doi.org/10.1016/S1044-579X(02)00134-7
Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, et al. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. Journal of Drug Delivery. 2011;2011:1–10. Available from: https://doi.org/10.1155/2011/465845
Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence. 2010;1(1):14. Available from: https://doi.org/10.1186/1758-907X-1-14
Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279–3330. Available from: https://doi.org/10.3390/cancers3033279
DeVita VT, Chu E. A History of cancer chemotherapy. Cancer Research. 2008;68(21):8643–8653. Available from: https://doi.org/10.1158/0008-5472.CAN-07-6611
Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy – a review. EJNMMI Radiopharmacy and Chemistry. 2019;4(1):27. Available from: https://doi.org/10.1186/s41181-019-0075-2
Gilman A. The initial clinical trial of nitrogen mustard. The American Journal of Surgery. 1963;105(5):574–578. Available from: https://doi.org/10.1016/0002-9610(63)90232-0
Gilman A. Symposium on advances in pharmacology resulting from war research: therapeutic applications of chemical warfare agents. Fed Proc. 1946;5:285-292.
Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). New England Journal of Medicine. 1948;238(23):787–793. Available from: https://doi.org/10.1056/NEJM194806032382301
Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Annals of the New York Academy of Sciences. 1954;60(2):195–199. Available from: https://doi.org/10.1111/j.1749-6632.1954.tb40008.x
Pearson OH, Eliel LP, Rawson RW, Dobriner K, Rhoads CP. Acth- and cortisone-induced regression of lymphoid tumors in man.A preliminary report. Cancer. 1949;2(6):943–945. Available from: https://doi.org/10.1002/1097-0142(194911)2:6<943::AID-CNCR2820020602>3.0.CO;2-P
Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. New England Journal of Medicine. 1958;259(2):66–74. Available from: https://doi.org/10.1056/NEJM195807102590204
Johnson TS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1963;23:1390-1427.
Oronsky BT, Reid T, Knox SJ, Scicinski JJ. The scarlet letter of alkylation: a mini review of selective alkylating agents. Translational Oncology. 2012;5(4):226–229. Available from: https://doi.org/10.1593/tlo.12187
Lehmann F, Wennerberg J. Evolution of nitrogen-based alkylating anticancer agents. Processes. 2021;9(2):377. Available from: https://doi.org/10.3390/pr9020377
El-Serafi I, Afsharian P, Moshfegh A, Hassan M, Terelius Y. Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation. PLOS ONE. 2015;10(11):e0141979. Available from: https://doi.org/10.1371/journal.pone.0141979
Prestayko AW, Baker LH, Crooke ST, ed. Nitrosoureas current status and new developments. New York: Acad Press; 1981.
Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Experim Clin Cancer Res. 2000;19(1):21-34.
Yu J, Xiao J, Yang Y, Cao B. Oxaliplatin-based doublets versus cisplatin or carboplatin-based doublets in the first-line treatment of advanced nonsmall cell lung cancer. Medicine. 2015;94(27):e1072. Available from: https://doi.org/10.1097/MD.0000000000001072
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews. 2004;56(2):185–229. Available from: https://doi.org/10.1124/pr.56.2.6
Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacology & Therapeutics. 2000;87(2–3):227–253. Available from: https://doi.org/10.1016/S0163-7258(00)00086-3
Fernández-Villa, Aguilar, Rojo. Folic acid antagonists: antimicrobial and immunomodulating mechanisms and applications. International Journal of Molecular Sciences. 2019;20(20):4996. Available from: https://doi.org/10.3390/ijms20204996
Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology. Berlin, Heidelberg: Springer; 2008. Available from: https://doi.org/10.1007/978-3-540-38918-7
van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics. 2013;14(7):799–811. Available from: https://doi.org/10.2217/pgs.13.54
Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. expert opinion on drug delivery. 2010;7(12):1399–1414. Available from: https://doi.org/10.1517/17425247.2010.527330
Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomedicine & Pharmacotherapy. 2017;88:635–643. Available from: https://doi.org/10.1016/j.biopha.2017.01.071
Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology. 2008;64(8):753–67. Available from: https://doi.org/10.1007/s00228-008-0478-6
Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27(9):1803–1812. Available from: https://doi.org/10.1038/leu.2013.173
Koeller J, Eble M. Mitoxantrone: a novel anthracycline derivative. Clin Pharm. 1988;7(8):574-581.
Sobell HM. Actinomycin and DNA transcription. Proceedings of the National Academy of Sciences. 1985;82(16):5328–31. Available from: https://doi.org/10.1073/pnas.82.16.5328
Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol. 1992;19(2 Suppl 5):3-8.
Verweij J, Pinedo HM. Mitomycin C. Anti-cancer drugs. 1990;1(1):5–14. Available from: https://doi.org/10.1097/00001813-199010000-00002
Sears JE, Boger DL. Total Synthesis of vinblastine, related natural products, and key analogues and development of inspired methodology suitable for the systematic study of their structure–function properties. Accounts of Chemical Research. 2015;48(3):653–662. Available from: https://doi.org/10.1021/ar500400w
Keglevich P, Hazai L, Kalaus G, Szántay C. Modifications on the basic skeletons of vinblastine and vincristine. Molecules. 2012;17(5):5893–5914. Available from: https://doi.org/10.3390/molecules17055893
Weaver BA. How taxol/paclitaxel kills cancer cells. Bement W, editor. Molecular Biology of the Cell. 2014;25(18):2677–2681. Available from: https://doi.org/10.1091/mbc.e14-04-0916
Delgado JL, Hsieh C-M, Chan N-L, Hiasa H. Topoisomerases as anticancer targets. Biochemical Journal. 2018;475(2):373–398. Available from: https://doi.org/10.1042/BCJ20160583
Wall ME. Camptothecin and taxol: discovery to clinic. Medicinal Research Reviews. 1998;18(5):299–314. Available from: https://doi.org/10.1002/(SICI)1098-1128(199809)18:5<299::AID-MED2>3.0.CO;2-O
Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. Journal of Ethnopharmacology. 2005;100(1–2):72–79. Available from: https://doi.org/10.1016/j.jep.2005.05.011
DeVita VT, Hellman A, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 2005.
Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology. 2006;147(S1):S269–S276. Available from: https://doi.org/10.1038/sj.bjp.0706399
Singh S, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens) structure-activity relationships. Current Medicinal Chemistry. 2000;7(2):211–247. Available from: https://doi.org/10.2174/0929867003375371
Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Reviews Cancer. 2001;1(2):118–129. Available from: https://doi.org/10.1038/35101072
Chen H-Z, Tian Y, Gao Y-H, Song X-C. The GEMS approach to stationary motions in the spherically symmetric spacetimes. Journal of High Energy Physics. 2004;2004(10):011–011. Available from: https://doi.org/10.1088/1126-6708/2004/10/011
Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Critical Reviews in Oncology/Hematology. 2016;97:275–290. Available from: https://doi.org/10.1016/j.critrevonc.2015.09.001
Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of Action of anti-Her2 monoclonal antibodies: scientific update on trastuzumab and 2c4. New Trends in Cancer for the 21stCentury. 2003;253–68. Available from: https://doi.org/10.1007/978-1-4615-0081-0_21
Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Reviews Drug Discovery. 2009;8(9):709–723. Available from: https://doi.org/10.1038/nrd2871
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. Journal of Clinical Investigation. 2015;125(5):1780–1789. Available from: https://doi.org/10.1172/JCI76094
Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988;242(4880):933–935. Available from: https://doi.org/10.1126/science.3263702
Rivera-Torres J, San José E. Src tyrosine kinase inhibitors: new perspectives on their immune, antiviral, and senotherapeutic potential. Frontiers in Pharmacology. 2019;10. Available from: https://doi.org/10.3389/fphar.2019.01011
Broome JD. L-asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 1981;65(Suppl 4):111-114.
Gambacorti-Passerini C, Antolini L, Mahon F-X, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. JNCI: Journal of the National Cancer Institute. 2011;103(7):553–561. Available from: https://doi.org/10.1093/jnci/djr060
Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6(4):386-394.
Harris PE, Bouloux P-MG. Endocrinology in Clinical Practice. CRC Press; 2014. Available from: https://doi.org/10.1201/b16712
Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin's disease. Semin Oncol. 1992;19(2 Suppl 5):38-44.
Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, et al. Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. Journal of Neuro-Oncology. 2014;117(2):253–259. Available from: https://doi.org/10.1007/s11060-014-1378-5
Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC Jr, Pinkus GS, et al.The mBACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol. 1987;24(2 Suppl 1):2-7.
Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin’s lymphoma? Cancer Investigation. 2006;24(4):461–465. Available from: https://doi.org/10.1080/07357900600705789
Ali N, Adil SN, Shaikh MU. Autologous Hematopoietic stem cell transplantation—10 years of data from a developing country. Stem Cells Translational Medicine. 2015;4(8):873–877. Available from: https://doi.org/10.5966/sctm.2015-0015
Mori Y, Shima H, Ihara H, Yabumoto H, Iwasaki A, Yoshioka M, et al. BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors. Hinyokika Kiyo. 1992;38(10):1139-1142.
Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2013;88(3):225–235. Available from: https://doi.org/10.1002/ajh.23390
Cooper K, Picot J, Bryant J, Clegg A. Comparative cost-effectiveness models for the treatment of multiple myeloma. International Journal of Technology Assessment in Health Care. 2014;30(1):90–97. Available from: https://doi.org/10.1017/S0266462313000615
Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, et al. Daratumumab for the management of newly diagnosed and relapsed/refractory multiple myeloma: current and emerging treatments. Frontiers in Oncology. 2021;10. Available from: https://doi.org/10.3389/fonc.2020.624661
Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2004;22(11):2084–91. Available from: https://doi.org/10.1200/JCO.2004.11.069
Comis RL. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer. Semin Oncol. 1986;13(3 Suppl 3):40-44.
Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol. 1995;22(2 Suppl 5):5-19.
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker Research. 2014;2(1). Available from: https://doi.org/10.1186/2050-7771-2-12
Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non‐Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Science. 2021;112(7):2607–2624. Available from: https://doi.org/10.1111/cas.14933
Shaikh H, Umar S, Sial M, Christou A, Kulkarni A. A case of secondary sclerosing cholangitis in the setting of non-Hodgkin’s lymphoma. Cureus. 2019;11(5):e4707. Available from: https://doi.org/10.7759/cureus.4707
Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Practice. 1998;6(1):13–21. Available from: https://doi.org/10.1046/j.1523-5394.1998.1998006013.x
Rohde D, Brehmer B, Kapp T, Valdor M, Jakse G. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV). Urological Research. 1998;26(4):249–257. Available from: https://doi.org/10.1007/s002400050053
Horning SJ. Risk, Cure and complications in advanced Hodgkin disease. Hematology. 2007;2007(1):197–203. Available from: https://doi.org/10.1182/asheducation-2007.1.197
Kaliki S. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Archives of Ophthalmology. 2011;129(11):1422–1427. Available from: https://doi.org/10.1001/archophthalmol.2011.289
Farrar MC, Jacobs TF. Paclitaxel. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/30725602/
Maruyama D, Tobinai K, Chou T, Taniwaki M, Shumiya Y, Iida S. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. Cancer Science. 2018;109(10):3245–3252. Available from: https://doi.org/10.1111/cas.13753
Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, et al. ChlVPP chemotherapy in children with stage IV Hodgkin’s disease: results of the UKCCSG HD 8201 and HD 9201 studies. British Journal of Haematology. 2002;119(3):647–51. Available from: https://doi.org/10.1046/j.1365-2141.2002.03927.x
Misra S, Yeshala SK, Singh S, Singh RK, Maria Das KJ, Kumar S, et al. A pilot study of perioperative cisplatin-capecitabine chemotherapy with preoperative chemoradiation for resectable gastric cancers. American Journal of Clinical Oncology. 2021;44(9):475–481. Available from: https://doi.org/10.1097/COC.0000000000000844
Hagberg CA, Gottumukkala VNR, Riedel BJ, Nates JL, Buggy DJ. Perioperative care of the cancer patient. Philadelphia, PA: Elsevier; 2022.
Yoshida T, Yonese J, Tsukamoto T, Kitsukawa S, Kin T, Maeda Y, et al. Treatment results of vip (etoposide, ifosfamide and cisplatin) chemotherapy as a first-line therapy in metastatic germ cell tumors. The Japanese Journal of Urology. 2000;91(2):55–61. Available from: https://doi.org/10.5980/jpnjurol1989.91.55
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai B-C, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. 2017;(8):CD004064. Available from: https://doi.org/10.1002/14651858.CD004064.pub4
Jung S-H, Park H, Ahn J-S, Yang D-H, Kim M-Y, Kim Y-K, et al. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. International Journal of Hematology. 2012;97(1):92–7. Available from: https://doi.org/10.1007/s12185-012-1237-0
Rees JK, Sandler RM, Challener J, Hayhoe FG. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: dat. British Journal of Cancer. 1977;36(6):770–776. Available from: https://doi.org/10.1038/bjc.1977.260
Jeon SY, Yhim H-Y, Kim HS, Kim J-A, Yang D-H, Kwak J-Y. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation. The Korean Journal of Internal Medicine. 2018;33(6):1169–1181. Available from: https://doi.org/10.3904/kjim.2016.163
Coleman M, Leonard J, Shuster MW, Kaufman TP. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl. 2001;64:41-45.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine. 2019;381(7):626–636. Available from: https://doi.org/10.1056/NEJMoa1904059
Roskoski R. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research. 2018;135:239–258. Available from: https://doi.org/10.1016/j.phrs.2018.08.013
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. New England Journal of Medicine. 2007;357(17):1695–1704. Available from: https://doi.org/10.1056/NEJMoa071028
Desar IME, Fleuren EDG, van der Graaf WTA. Systemic treatment for adults with synovial sarcoma. Current Treatment Options in Oncology. 2018;19(2):13. Available from: https://doi.org/10.1007/s11864-018-0525-1
Watanabe K, Sato M, Yamamoto M, Ikarashi M, Hagio K, Tomioka N, et al. Safety and tolerance of dose-dense epirubicin and cyclophosphamide (EC) with Pegfilgrastim for Japanese patients with early breast cancer. Gan To Kagaku Ryoho. 2016;43(4):435-438.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006;355(1):11–20. Available from: https://doi.org/10.1056/NEJMoa055531
Petrioli R, Francini E, Roviello F, Marrelli D, Fiaschi AI, Laera L, et al. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemotherapy and Pharmacology. 2015;75(5):941–7. Available from: https://doi.org/10.1007/s00280-015-2715-x
Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chinese Journal of Cancer Research. 2020;32(2):263–270. Available from: https://doi.org/10.21147/j.issn.1000-9604.2020.02.13
Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693. Available from: https://doi.org/10.1182/blood.V99.8.2685
Öztürk MA, Barışta İ, Altundağ MK, Türker A, Yalçın Ş, Çelik İ, et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin’s lymphoma: results of a single-center study of 32 patients. Chemotherapy. 2002;48(5):252–8. Available from: https://doi.org/10.1159/000066768
Fujimura T, Yoshino K, Kato H, Fujisawa Y, Nakamura Y, Yamamoto Y, et al. Case series of BRAF‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. The Journal of Dermatology. 2020;48(3):397–400. Available from: https://doi.org/10.1111/1346-8138.15688
Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017;18(11):1467–1482. Available from: https://doi.org/10.1016/S1470-2045(17)30566-1
Veneziano G, Wosiek J. A supersymmetric matrix model: III. Hidden SUSY in statistical systems. Journal of High Energy Physics. 2006;2006(11):030–030. Available from: https://doi.org/10.1088/1126-6708/2006/11/030
Wu W, Chen J, Deng H, Jin L, He Z, Rao N, et al. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. BMC Cancer. 2021;21(1):862. Available from: https://doi.org/10.1186/s12885-021-08612-y
Al-Batran S-E, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology. 2008;19(11):1882–1887. Available from: https://doi.org/10.1093/annonc/mdn403
Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology. 2001;12(10):1455–1460. Available from: https://doi.org/10.1023/A:1012551809100
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 2020;395(10242):2008–2020. Available from: https://doi.org/10.1016/S0140-6736(20)30974-0
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309. Available from: https://doi.org/10.1182/blood-2015-09-667675
Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, et al. Role of chemotherapy in vulvar cancers: time to rethink standard of care? Cancers. 2021;13(16):4061. Available from: https://doi.org/10.3390/cancers13164061
Yu K-D, Ye F-G, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer. JAMA Oncology. 2020;6(9):1390. Available from: https://doi.org/10.1001/jamaoncol.2020.2965
Seo M-D, Lee K-W, Lim JH, Yi HG, Kim D-Y, Oh D-Y, et al. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Japanese Journal of Clinical Oncology. 2008;38(9):589–595. Available from: https://doi.org/10.1093/jjco/hyn078
Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll H-J, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clinical Colorectal Cancer. 2015;14(1):1–10. Available from: https://doi.org/10.1016/j.clcc.2014.11.002
Song Y, Li WW, Huang J. Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2017;39(5):380-383. Available from: https://doi.org/10.3760/cma.j.issn.0253-3766.2017.05.012
Solimando DA, Waddell JA. Capecitabine and gemcitabine (CapGem, CG, GemCap) for advanced pancreatic and biliary tract cancer. Hospital Pharmacy. 2014;49(2):127–133. Available from: https://doi.org/10.1310/hpj4902-127
Bae K-S, Ahn KI, Jeon SH, Huh J-S, Chang S-G. Efficacy of combined gemcitabine/cisplatin chemotherapy for locally advanced or metastatic urothelial cancer. Cancer Research and Treatment. 2006;38(2):78-83. Available from: https://doi.org/10.4143/crt.2006.38.2.78
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer. 2010;103(4):469–474. Available from: https://doi.org/10.1038/sj.bjc.6605779
Zhong W-Z, Chen K-N, Chen C, Gu C-D, Wang J, Yang X-N, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage iiia-n2 egfr-mutant non–small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase ii study. Journal of Clinical Oncology. 2019;37(25):2235–2245. Available from: https://doi.org/10.1200/JCO.19.00075
Ashaye AO, Khankhel Z, Xu Y, Fahrbach K, Mokgokong R, Orme ME, et al. A comparative evaluation of gemtuzumab ozogamicin+daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia. Future Oncology. 2019;15(6):663–681. Available from: https://doi.org/10.2217/fon-2018-0512
Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Annals of Oncology. 2003;14:i5–i10. Available from: https://doi.org/10.1093/annonc/mdg702
Zraik IM, Heß-Busch Y. Management of chemotherapy side effects and their long-term sequelae. Der Urologe. 2021;60(7):862–871. Available from: https://doi.org/10.1007/s00120-021-01569-7
Sheng IY, Ornstein MC.Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date. Cancer Management and Research. 2020;12:4871–4881. Available from: https://doi.org/10.2147/CMAR.S202017
Boers-Sonderen MJ, Desar IME, Koopman M, Punt CJ, van Herpen CML. Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer. Acta Oncologica. 2013;52(8):1778–1778. Available from: https://doi.org/10.3109/0284186X.2013.806994
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine. 2016;374(17):1621–1634. Available from: https://doi.org/10.1056/NEJMoa1516282
Smith IE, Powles TJ. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. Oncology. 1993;50(1):9–15. Available from: https://doi.org/10.1159/000227241
Patton SE, Hall MC, Ozen H. Bladder cancer. Current Opinion in Oncology. 2002;14(3):265–272. Available from: https://doi.org/10.1097/00001622-200205000-00003
Nau KC, Lewis WD. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2008;78(7):853-859.
Kim M, Williams S. Midostaurin in combination with standard chemotherapy for treatment of newly diagnosed fms-like tyrosine kinase 3 (FLT3) mutation–positive acute myeloid leukemia. Annals of Pharmacotherapy. 2017;52(4):364–369. Available from: https://doi.org/10.1177/1060028017747900
Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. New England Journal of Medicine. 2005;352(25):2589–2597. Available from: https://doi.org/10.1056/NEJMoa043623
Isogai R, Fukao M, Kawada A. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. The Journal of Dermatology. 2007;34(8):556–560. Available from: https://doi.org/10.1111/j.1346-8138.2007.00330.x
Bower M, Fife K, Holden L, Paradinas FJ, Rustin GJS, Newlands ES. Chemotherapy for ovarian germ cell tumours. European Journal of Cancer. 1996;32(4):593–597. Available from: https://doi.org/10.1016/0959-8049(95)00598-6
Pratt G. Panobinostat plus bortezomib and dexamethasone for relapsed myeloma. The Lancet Haematology. 2016;3(11):e498–e499. Available from: https://doi.org/10.1016/S2352-3026(16)30133-8
Biersack B. Relations between approved platinum drugs and non-coding RNAs in mesothelioma. Non-coding RNA Research. 2018;3(4):161–173. Available from: https://doi.org/10.1016/j.ncrna.2018.08.001
Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park). 2004;18(8 Suppl 5):54-62.
Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl‐Goldstein K, Kaya H, et al. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. British Journal of Haematology. 2019;188(4):501–510. Available from: https://doi.org/10.1111/bjh.16213
Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL. Procarbazine, lomustine and vincristine for recurrent high-grade glioma. Cochrane Database of Systematic Reviews. 2017;(7):CD011773. Available from: https://doi.org/10.1002/14651858.CD011773.pub2
Cummin T, Johnson P. Lymphoma: turning biology into cures. Clinical Medicine. 2016;16(Suppl 6):s125–s129. Available from: https://doi.org/10.7861/clinmedicine.16-6-s125
Carbone J, Perez-Fernandez R, Muñoz A, Sabin P, Carreño L, Fernandez-Cruz E. Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren’s syndrome-associated B-cell non-Hodgkin’s lymphoma. Clinical Reviews in Allergy &; Immunology. 2007;34(1):80–84. Available from: https://doi.org/10.1007/s12016-007-8025-2
Lisenko K, McClanahan F, Schöning T, Schwarzbich MA, Cremer M, Dittrich T, et al. Minimal renal toxicity after rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. BMC Cancer. 2016;16(1):267. Available from: https://doi.org/10.1186/s12885-016-2289-y
Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93(12):1829–1836. Available from: https://doi.org/10.3324/haematol.13440
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute Trial. Journal of Clinical Oncology. 2014;32(4):282–287. Available from: https://doi.org/10.1200/JCO.2013.49.7586
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, et al. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & Lymphoma. 2009;50(5):741–748. Available from: https://doi.org/10.1080/10428190902853136
Jeon YW, Lim ST, Gwak H, Park SY, Suh YJ. Clinical Impact of primary prophylactic pegfilgrastim in breast cancer patients receiving adjuvant docetaxel-doxorubicin-cyclophosphamide chemotherapy. Journal of Breast Cancer. 2020;23(5):521-532. Available from: https://doi.org/10.4048/jbc.2020.23.e52
Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of Clinical Oncology. 2005;23(27):6549–6555. Available from: https://doi.org/10.1200/JCO.2005.19.638
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, et al. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Breast Cancer. 2016;24(1):63–68. Available from: https://doi.org/10.1007/s12282-016-0666-7
Bergen ES, Binter A, Starzer AM, Heller G, Kiesel B, Tendl-Schulz K, et al. Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. Therapeutic Advances in Medical Oncology. 2021;13:175883592110090. Available from: https://doi.org/10.1177/17588359211009002
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatric Blood & Cancer. 2006;47(1):22–29. Available from: https://doi.org/10.1002/pbc.20820
Loehrer PJ Sr, Williams SD, Einhorn LH. Ifosfamide in testicular cancer: the Indiana University experience. Semin Oncol. 1989;16(1 Suppl 3):96-101.
Jaffe N, Paed D, Traggis D, Salian S, Cassady JR. Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer. 1976;38(5):1925–1930. Available from: https://doi.org/10.1002/1097-0142(197611)38:5<1925::AID-CNCR2820380510>3.0.CO;2-J
Whelan J, Le Deley M-C, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. Journal of Clinical Oncology. 2018;36(31):3110–9. Available from: https://doi.org/10.1200/JCO.2018.78.2516
Hussein M. Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma. Clinical Lymphoma. 2003;4:S18–S22. Available from: https://doi.org/10.3816/CLM.2003.s.004
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.